FIELD: medicine.
SUBSTANCE: invention relates to immunology and medicine, particularly to dosage regimens of antibodies to TIGIT, suitable for treating cancer. Invention also relates to a dosing regimen in a combination therapy which involves administering an antibody to programmed cell death protein 1 (PD-1) or programmed death protein ligand 1 (PD-L1) and an antibody to TIGIT.
EFFECT: invention provides a method of combined therapy of cancer with increased safety and efficiency.
31 cl, 9 dwg, 17 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
